Class summary at a glance.

Every drug in the Anthelmintic class tracked across NADAC, Part D Formulary, Part D Spending, FDA Orange Book, and shortage data. Ranked below by CY24 Part D spend. Click any molecule for the full drug profile.

Molecules in class: 4tracked in Part D
CY24 Part D spend: $19.7Mcombined across class
Total Rx claims: 24K18K unique beneficiaries
Generic mfrs (active): 8across all molecules

Every drug in this class, ranked by Part D spend.

CY2024 dataCMS Part D Spending Dashboard

Mebendazole

Brand: VERMOX · 3K Part D claims (CY24) · 2K beneficiaries · First FDA approval: 2016-10-20

1 generic mfrs

Low NADAC—

→

Avg plan cost—

Part D spend $10.1M

Class share

51%

of class CY24 spend

View profile →

Albendazole

Brand: ALBENZA · 19K Part D claims (CY24) · 14K beneficiaries · First FDA approval: 1996-06-11

6 generic mfrs 52 plans require PA

Low NADAC$4.40

→

Avg plan cost$4.40

Part D spend $7.8M 1× spread, current vs floor

Class share

39%

of class CY24 spend

View profile →

Praziquantel

Brand: Biltricide · 2K Part D claims (CY24) · 2K beneficiaries · First FDA approval: 2011-04-21

1 generic mfrs 0 plans require PA

Low NADAC$54.65

→

Avg plan cost$54.65

Part D spend $1.8M 1× spread, current vs floor

Class share

of class CY24 spend

View profile →

Triclabendazole

Brand: EGATEN · — Part D claims (CY24) · First FDA approval: 2019-02-13

Brand-only (no generics)

Low NADAC—

→

Avg plan cost—

Part D spend —

Class share

of class CY24 spend

View profile →

Class summary at a glance.

Every drug in this class, ranked by Part D spend.

Related questions.